The proposal submitted jointly by 46 members has been responded to!

At about 4:00 p.m on March 12, the second session of the 13th CPPCC National Committee Medical and health sector group meeting just ended Chen Shifei, a member of the Party group and deputy director of the State Food and drug administration, and a group of 5 people came to the CPPCC member's residence of the medical and health sector to communicate with some CPPCC members of the medical and health sector on the drug review reform "Thank you very much for your concern and support The State Food and Drug Administration attaches great importance to the proposals of Qin Shukui, Ge Junbo and other members and the speech at the joint group meeting on March 7 After attending the joint group meeting, I reported to the leading group of the Bureau as soon as possible, and held a meeting to study and solve relevant problems This time, we are here to get a more timely and clear understanding of the opinions and suggestions of the committee members, listen to the opinions for further deepening the reform of the drug review and approval system, and seek good policies " Chen Shifei is open-minded and sincere During the two sessions, the reform of drug review and approval system in China was highly concerned by the representatives of the two sessions In 2018, China approved a total of 48 new drugs to be listed, more than double the 20 in 2016; in 2018, the number of new anti-cancer drugs to be listed in China reached 18, an increase of 157% over 2017, while the approval time was half shorter than before 2018 These achievements benefit Chinese patients At the same time, Qin Shukui, director of the cancer center of the PLA Eastern theater general hospital, Ge Junbo, academician of the Chinese Academy of Sciences and director of Cardiology Department of Zhongshan Hospital Affiliated to Fudan University, and other 46 CPPCC members jointly submitted a proposal to actively play the role of the Advisory Committee of drug review experts of the State Food and Drug Administration and further improve the drug review in China Overall level of review batch On March 7, Chen Shifei and other relevant heads of state drug regulatory departments attended the joint group meeting of medical and health sectors At the meeting, Qin Shukui and other members put forward relevant suggestions on how to further deepen the drug trial reform and strengthen the construction of reviewer team "In recent years, with the concern of the State Council, the State Food and drug administration has further promoted the reform of drug examination, and the staff of drug examination center has increased from 200 to nearly 800 In general, we have worked very hard, many reviewers have performed well, and the achievements are obvious to all However, due to the large number of new personnel, the professional level of evaluation needs to be further improved In addition, we need to find ways to attract and retain outstanding talents " At the communication meeting, committee member Qin Shukui said straight "There is a relative shortage of drug reviewers, especially high-level reviewers in China To further deepen the reform of drug review, we must solve the problem of low efficiency of review due to lack of manpower " Commissioner Ge Junbo also said frankly At the communication meeting, Chen Shifei and his delegation listened carefully to the opinions and suggestions of the committee members, recorded the key contents one by one, and fully exchanged views with the committee members on issues such as industrial development and the listing of domestic new drugs Both sides and members of the CPPCC are extremely frank Chen Shifei said that the State Food and Drug Administration will fully adopt the opinions and suggestions proposed by the committee members and translate them into specific policies, measures, tasks and objectives, further improve the scientificity, professionalism and standardization level of the review work, help to meet the clinical needs, promote the high-quality development of the pharmaceutical industry, and make the latest achievements in scientific and technological progress benefit patients at the fastest speed "This is an unprecedented experience: after the proposal was submitted, it received immediate feedback; before the CPPCC conference, the state drug regulatory department immediately came to listen to the opinions, answer the doubts and respond to the content of the proposal in a timely manner, reflecting the responsibilities and responsibilities of the drug regulatory department." General Chen Wei, member of the CPPCC National Committee and director of the Institute of biological products, Academy of Medical Sciences, PLA Academy of Military Sciences, said she was warmed by the initiative of the personnel of the State Drug Administration "The zero distance communication enables us to further understand the drug review and approval work in China and the next work plan, and deepen our understanding of drug review reform The initiative of the State Food and Drug Administration reflects a highly responsible attitude towards the cause and the people, and we highly appreciate it It is believed that the reform of drug review and approval system in China will be further deepened and improved " After the meeting, members of Qin Shukui said so (Lu Yue, reporter of China Medical News)